|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Collaboration revenue | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Other income, net: | |||||
| Interest income | |||||
| Change in fair value of investments, net | |||||
| Loss from equity method investment | |||||
| Change in fair value of contingent consideration | |||||
| Total other income, net | |||||
| Net loss | |||||
| Net loss per share, basic | |||||
| Net loss per share, diluted | |||||
| Weighted average shares outstanding, basic | |||||
| Weighted average shares outstanding, diluted | |||||
| Other comprehensive income (loss): | |||||
| Unrealized gain on marketable securities | |||||
| Other comprehensive gain (loss) from equity method investment | |||||
| Other comprehensive gain from equity method investment | |||||
| Comprehensive loss | |||||
Loading...